Shilpa Medicare Limited — Investor Meet, 14-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Shilpa Medicare reported total revenues of INR 320 crore, reflecting an 11% year-over-year growth. EBITDA rose by 20% to INR 82 crore, with margins at 26%. Notably, profit after tax surged to INR 32 crore from INR 5 crore a year earlier. Gross margins improved to 72%, driven by better performance in formulations and biologics, despite a 10% year-over-year decline in the API business, attributed to purchasing shifts from key clients.

2. Future Outlook and Growth Drivers: Management emphasized a positive outlook for FY '26, mainly driven by launches of new oncology molecules like Nilotinib and Axitinib, as well as strengthening revenues from formed products and the ongoing transition from licensing to commercial sales. The focus is on expanding the CDMO segment and penetrating export markets.

3. Order Book and Operational Updates: The company anticipates revenue growth across its segments, especially from new oncology product launches and enhanced API offerings. Notable products in the pipeline include complex APIs for oncology and non-oncology segments, which are expected to contribute significantly to growth.

4. Analyst Q&A Insights: Key topics included queries about revenue projections from new products, with management indicating that substantial growth is likely from various new NCEs. Concerns about API pricing pressures were raised; however, management noted their focus on complex products shields them somewhat from these fluctuations. Discussions also covered the company's balance sheet improvements due to reduced interest burdens from prior debt repayments.

5. Market or Regulatory Updates: The company successfully completed FDA remediation actions, allowing further market access for multiple products. Regulatory approvals in Europe for APIs are seen as pivotal for future growth.

6. Strategic Focus Areas: Shilpa's strategy emphasizes innovation in drug development, operational efficiency, and diversification in product offerings, reinforcing its competitive stance.

7. Investor Insight: Given the company’s improved financial health, strategic product launches, and robust pipeline, a ‘buy’ position may be justified, contingent on sustained operational execution and market dynamics. The strong cash flow and positive outlook for major molecules enhance Shilpa's attractiveness as an investment.